{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:16:22Z","timestamp":1778541382451,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15876-9","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T05:54:38Z","timestamp":1774763678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interrelation between lncRNA HOTAIR and EZH2 expression and progression free survival during endocrine treatment in breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhangzan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Muritti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anieta","family":"Sieuwerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanja","family":"de Weerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieke","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice P.H.M.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"issue":"6","key":"15876_CR1","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477\u201395.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"15876_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, et al. Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736\u201347.","journal-title":"Ann Oncol"},{"issue":"6797","key":"15876_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"3","key":"15876_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5306\/wjco.v5.i3.283","volume":"5","author":"R Shah","year":"2014","unstructured":"Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5(3):283\u201398.","journal-title":"World J Clin Oncol"},{"key":"15876_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","volume":"116","author":"N Fuentes","year":"2019","unstructured":"Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019;116:135\u201370.","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"1","key":"15876_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1677\/ERC-09-0062","volume":"17","author":"T van Agthoven","year":"2010","unstructured":"van Agthoven T, et al. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer. 2010;17(1):215\u201330.","journal-title":"Endocr Relat Cancer"},{"issue":"9472","key":"15876_CR7","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"G Collaborative","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019, Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u2013717.","journal-title":"Lancet"},{"key":"15876_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233\u201347.","journal-title":"Annu Rev Med"},{"issue":"3","key":"15876_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1152\/physrev.00024.2015","volume":"96","author":"A Wicki","year":"2016","unstructured":"Wicki A, et al. Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiol Rev. 2016;96(3):805\u201329.","journal-title":"Physiol Rev"},{"issue":"4","key":"15876_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4149\/neo_2014_075","volume":"61","author":"B Cai","year":"2014","unstructured":"Cai B, et al. HOTAIR: a cancer-related long non-coding RNA. Neoplasma. 2014;61(4):379\u201391.","journal-title":"Neoplasma"},{"key":"15876_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1476-4598-13-92","volume":"13","author":"XH Liu","year":"2014","unstructured":"Liu XH, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014;13:92.","journal-title":"Mol Cancer"},{"issue":"1","key":"15876_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-023-01765-3","volume":"22","author":"GSR Raju","year":"2023","unstructured":"Raju GSR, et al. HOTAIR: a potential metastatic, drug-resistant and prognostic regulator of breast cancer. Mol Cancer. 2023;22(1):65.","journal-title":"Mol Cancer"},{"issue":"21","key":"15876_CR13","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/onc.2015.340","volume":"35","author":"X Xue","year":"2016","unstructured":"Xue X, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35(21):2746\u201355.","journal-title":"Oncogene"},{"issue":"2","key":"15876_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10549-010-0836-9","volume":"125","author":"EA Reijm","year":"2011","unstructured":"Reijm EA, et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat. 2011;125(2):387\u201394.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"15876_CR15","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1093\/annonc\/mdu391","volume":"25","author":"EA Reijm","year":"2014","unstructured":"Reijm EA, et al. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer. Ann Oncol. 2014;25(11):2185\u201390.","journal-title":"Ann Oncol"},{"key":"15876_CR16","doi-asserted-by":"crossref","unstructured":"Xia Z et al. The PURB-HOTAIR complex regulates p53-dependent promoter-specific transcriptional activation. Nat Struct Mol Biol. 2025;32(9):1669\u201382.","DOI":"10.1038\/s41594-025-01597-3"},{"issue":"4","key":"15876_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/mc.23878","volume":"64","author":"X Lai","year":"2025","unstructured":"Lai X, et al. HGF\/c-Met Promotes Breast Cancer Tamoxifen Resistance Through the EZH2\/HOTAIR-miR-141\/200a Feedback Signaling Pathway. Mol Carcinog. 2025;64(4):769\u201383.","journal-title":"Mol Carcinog"},{"issue":"11","key":"15876_CR18","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/1535-7163.MCT-23-0314","volume":"23","author":"W Wang","year":"2024","unstructured":"Wang W, et al. Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2. Mol Cancer Ther. 2024;23(11):1666\u201379.","journal-title":"Mol Cancer Ther"},{"key":"15876_CR19","first-page":"100541","volume":"31","author":"T Iizuka","year":"2022","unstructured":"Iizuka T, et al. The combined use of long non-coding RNA HOTAIR and polycomb group protein EZH2 as a prognostic marker of lung adenocarcinoma. Cancer Treat Res Commun. 2022;31:100541.","journal-title":"Cancer Treat Res Commun"},{"issue":"3","key":"15876_CR20","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F","volume":"39","author":"JL Hayward","year":"1977","unstructured":"Hayward JL, et al. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977;39(3):1289\u201394.","journal-title":"Cancer"},{"issue":"14","key":"15876_CR21","first-page":"5407","volume":"61","author":"JA Foekens","year":"2001","unstructured":"Foekens JA, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001;61(14):5407\u201314.","journal-title":"Cancer Res"},{"issue":"20","key":"15876_CR22","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.1158\/1078-0432.CCR-05-0560","volume":"11","author":"AM Sieuwerts","year":"2005","unstructured":"Sieuwerts AM, et al. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res. 2005;11(20):7311\u201321.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"15876_CR23","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1373\/clinchem.2006.082800","volume":"53","author":"AM Sieuwerts","year":"2007","unstructured":"Sieuwerts AM, et al. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem. 2007;53(7):1280\u20138.","journal-title":"Clin Chem"},{"issue":"4","key":"15876_CR24","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1200\/JCO.2008.17.1462","volume":"27","author":"T van Agthoven","year":"2009","unstructured":"van Agthoven T, et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol. 2009;27(4):542\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"15876_CR25","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/sj.bjc.6605423","volume":"101","author":"T van Agthoven","year":"2009","unstructured":"van Agthoven T, et al. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Br J Cancer. 2009;101(11):1824\u201332.","journal-title":"Br J Cancer"},{"issue":"7291","key":"15876_CR26","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08975","volume":"464","author":"RA Gupta","year":"2010","unstructured":"Gupta RA, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071\u20136.","journal-title":"Nature"},{"issue":"15","key":"15876_CR27","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1093\/hmg\/ddw177","volume":"25","author":"MJ Milevskiy","year":"2016","unstructured":"Milevskiy MJ, et al. Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer. Hum Mol Genet. 2016;25(15):3269\u201383.","journal-title":"Hum Mol Genet"},{"key":"15876_CR28","doi-asserted-by":"publisher","first-page":"143955","DOI":"10.1016\/j.gene.2019.143955","volume":"714","author":"PE Tokgun","year":"2019","unstructured":"Tokgun PE, et al. MYC-driven regulation of long non-coding RNA profiles in breast cancer cells. Gene. 2019;714:143955.","journal-title":"Gene"},{"issue":"2","key":"15876_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1158\/0008-5472.CAN-14-3607","volume":"76","author":"Y Li","year":"2016","unstructured":"Li Y, et al. HBXIP and LSD1 Scaffolded by lncRNA Hotair Mediate Transcriptional Activation by c-Myc. Cancer Res. 2016;76(2):293\u2013304.","journal-title":"Cancer Res"},{"issue":"8","key":"15876_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/bjc.2016.46","volume":"114","author":"AR Green","year":"2016","unstructured":"Green AR, et al. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer. 2016;114(8):917\u201328.","journal-title":"Br J Cancer"},{"issue":"1","key":"15876_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13148-019-0624-2","volume":"11","author":"Y Ren","year":"2019","unstructured":"Ren Y, et al. Targeted design and identification of AC1NOD4Q to block activity of HOTAIR by abrogating the scaffold interaction with EZH2. Clin Epigenetics. 2019;11(1):29.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"15876_CR32","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41598-017-00966-3","volume":"7","author":"AR Ozes","year":"2017","unstructured":"Ozes AR, et al. Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Sci Rep. 2017;7(1):894.","journal-title":"Sci Rep"},{"key":"15876_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12967-015-0489-x","volume":"13","author":"S Tao","year":"2015","unstructured":"Tao S, He H, Chen Q. Estradiol induces HOTAIR levels via GPER-mediated miR-148a inhibition in breast cancer. J Transl Med. 2015;13:131.","journal-title":"J Transl Med"},{"key":"15876_CR34","doi-asserted-by":"publisher","first-page":"8765","DOI":"10.1038\/srep08765","volume":"5","author":"Y Gokmen-Polar","year":"2015","unstructured":"Gokmen-Polar Y, et al. Prognostic impact of HOTAIR expression is restricted to ER-negative breast cancers. Sci Rep. 2015;5:8765.","journal-title":"Sci Rep"},{"key":"15876_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.breast.2019.05.003","volume":"46","author":"YL Wang","year":"2019","unstructured":"Wang YL, et al. Long non-coding RNA HOTAIR in circulatory exosomes is correlated with ErbB2\/HER2 positivity in breast cancer. Breast. 2019;46:64\u20139.","journal-title":"Breast"},{"issue":"1","key":"15876_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13058-016-0765-6","volume":"18","author":"M Abubakar","year":"2016","unstructured":"Abubakar M, et al. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016;18(1):104.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"15876_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdx651","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, et al. Characterization of male breast cancer: results of the EORTC 10085\/TBCRC\/BIG\/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405\u201317.","journal-title":"Ann Oncol"},{"key":"15876_CR38","doi-asserted-by":"publisher","first-page":"216445","DOI":"10.1016\/j.canlet.2023.216445","volume":"578","author":"L Chen","year":"2023","unstructured":"Chen L, et al. Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer. Cancer Lett. 2023;578:216445.","journal-title":"Cancer Lett"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15876-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15876-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:47:17Z","timestamp":1778539637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15876-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15876"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15876-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study analyzed a cohort of 1,683 patients diagnosed with primary resectable breast cancer at Erasmus MC (Rotterdam, the Netherlands) between 1979 and 1996. The study was performed in accordance with the principles of the Declaration of Helsinki and the local law. Coded, leftover patient material was used in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands (\n                      \n                      ). According to these national guidelines, this work was not subject to the Medical Research Involving Human Subjects Act (WMO; METC 02.593).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give their consent for publication in the Journal BMC Cancer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"596"}}